Three-Drug showdown aims to end stent pain for kidney stone patients
NCT ID NCT06803030
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares three common drugs—tamsulosin, solifenacin, and mirabegron—to see which one works best for reducing symptoms caused by ureteral stents placed after kidney stone surgery. About 189 adults will take one of the three pills daily and report their symptoms using a questionnaire. The goal is to find the most effective option to improve comfort while the stent is in place.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tamsulosin, solifenacin, mirabegron
What this could lead to
If successful, this could identify the best drug to reduce pain and urinary symptoms caused by ureteral stents, improving comfort for patients after stone surgery.
What could go wrong
This is a moderate-sized Phase 3 trial, but results may not apply to all stent patients. The drugs have known side effects like dry mouth or dizziness, and the best option may still leave some symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URETERAL STENT-RELATED SYMPTOM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NAMS, Bir Hospital
RECRUITINGKathmandu, Bagmati, 44600, Nepal
Contact Phone: •••-•••-•••• Email: •••••@•••••